-
公开(公告)号：US20240350627A1
公开(公告)日：2024-10-24
申请号：US18292586
申请日：2022-07-28
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Chihiro Take , Akiko Yamaguchi , Gary Shapiro
IPC: A61K39/00 , A61P35/00 , C07K14/52 , C07K14/54 , C07K14/705 , C07K14/725 , C07K16/30 , C12N5/0783
CPC classification number: A61K39/4611 , A61K39/4631 , A61K39/4635 , A61K39/464468 , A61P35/00 , C07K14/521 , C07K14/5418 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/30 , C12N5/0636 , C07K2317/53 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2510/00
Abstract: Disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes human mesothelin, a CD8 hinge region, a CD8 transmembrane region, a 4-1BB intracellular region and a CD3ζ intracellular region; a polynucleotide encoding IL-7; and a polynucleotide encoding CCL19. Also disclosed herein include vectors, modified immune cells, and pharmaceutical compositions comprising the nucleic acid molecules and methods of use.
-
公开(公告)号：US12123021B2
公开(公告)日：2024-10-22
申请号：US17707725
申请日：2022-03-29
Applicant: KSQ Therapeutics, Inc.
Inventor： Micah Benson , Jason J. Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael R. Schlabach , Noah Jacob Tubo , James Martin Kaberna, II
IPC: C12N5/0783 , A61K35/17 , A61P35/00 , A61P35/04 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/32 , C12N9/22 , C12N15/11 , C12N15/113 , A61K38/00 , A61K39/00
CPC classification number: C12N5/0636 , A61K35/17 , A61P35/00 , A61P35/04 , C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K16/2863 , C07K16/32 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/1135 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/622 , C07K2319/30 , C12N2310/122 , C12N2310/14 , C12N2310/20 , C12N2310/531 , C12N2800/80
Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US12122831B2
公开(公告)日：2024-10-22
申请号：US17072842
申请日：2020-10-16
Applicant: Lentigen Technology, Inc.
Inventor： Dina Schneider , Rimas J. Orentas , Boro Dropulic , Peirong Hu
IPC: C07K16/28 , A61K35/17 , A61K38/00 , A61P35/02 , C07K14/705 , C07K14/725
CPC classification number: C07K16/2803 , A61K35/17 , A61P35/02 , C07K14/7051 , C07K14/70517 , C07K14/70521 , A61K38/00 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20240336680A1
公开(公告)日：2024-10-10
申请号：US18753205
申请日：2024-06-25
Applicant: ACCURUS BIOSCIENCES, INC.
Inventor： Haishan Lin , Richard Zhang
IPC: C07K16/28 , A61K47/68 , C07K14/705 , C07K14/725 , G01N33/68
CPC classification number: C07K16/28 , A61K47/6849 , C07K14/7051 , C07K14/70517 , C07K14/70578 , G01N33/6854 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/77 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
Abstract: Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibody, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.
-
公开(公告)号：US20240325445A1
公开(公告)日：2024-10-03
申请号：US18670684
申请日：2024-05-21
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： David DiLillo , Frank Delfino , Kevin Bray , Thomas Craig Meagher , Jessica Kirshner , Olga Sineshchekova
IPC: A61K35/17 , A61P35/02 , C07K14/705 , C07K14/725 , C07K16/28 , C12N15/85
CPC classification number: A61K35/17 , A61P35/02 , C07K14/7051 , C07K14/70517 , C07K16/2827 , C07K16/2878 , C12N15/85
Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.
-
公开(公告)号：US12102653B2
公开(公告)日：2024-10-01
申请号：US18312330
申请日：2023-05-04
Inventor： Michael Traxlmayr , Christian Obinger , Charlotte Brey , Manfred Lehner
IPC: C07K14/00 , A61K35/17 , C07K14/705 , C07K14/725 , C07K14/775 , A61K38/00
CPC classification number: A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/775 , A61K38/00 , C07K2319/70
Abstract: A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of
-
公开(公告)号：US20240309102A1
公开(公告)日：2024-09-19
申请号：US18733957
申请日：2024-06-05
Applicant: Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventor： Rimas J. Orentas , Dina Schneider , Boro Dropulic , Dimiter S. Dimitrov , Zhong Zhu
IPC: C07K16/28 , A61K35/17 , A61K38/00 , C07K14/705 , C07K14/725 , C12N15/10 , C12N15/86
CPC classification number: C07K16/2866 , A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C12N15/1037 , C12N15/86 , A61K38/00 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2740/15041
Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20240307539A1
公开(公告)日：2024-09-19
申请号：US18029400
申请日：2021-09-29
Applicant: INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCE , BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE
Inventor： Haoyi WANG , Beilei XU , Na LI , Na TANG
IPC: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N9/22 , C12N15/11 , C12N15/90
CPC classification number: A61K39/464404 , A61K39/4611 , A61K39/4631 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K16/2863 , C12N5/0636 , C12N9/22 , C12N15/11 , C12N15/907 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2310/20 , C12N2800/80
Abstract: The present invention relates to the field of biomedicines. Specifically, the present invention relates to a chimeric antigen receptor (CAR) targeting EGFR, a CAR-T cell containing the CAR, as well as a preparation method and use thereof.
-
公开(公告)号：US12091440B2
公开(公告)日：2024-09-17
申请号：US17127380
申请日：2020-12-18
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jiaxi Wu , Tong Zhang , Maria del Pilar Molina-Portela , Eric Smith , Chia-Yang Lin , Thomas Craig Meagher
IPC: C07K14/55 , A61K35/17 , A61K38/00 , A61K38/20 , A61K47/68 , A61P35/00 , C07K14/705 , C07K14/715 , C07K14/725 , C07K14/74
CPC classification number: C07K14/55 , A61K35/17 , A61K38/2013 , A61K47/6849 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70539 , C07K14/7155 , A61K38/00 , C07K2319/30
Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
-
公开(公告)号：US20240301028A1
公开(公告)日：2024-09-12
申请号：US18645201
申请日：2024-04-24
Applicant: Baylor College of Medicine
Inventor： David Quach , Cliona M. Rooney
IPC: C07K14/74 , A61K35/17 , A61K38/00 , A61P37/06 , C07K14/705 , C07K14/725 , C12N5/0783
CPC classification number: C07K14/70539 , A61K35/17 , A61P37/06 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C12N5/0636 , A61K38/00 , C07K2319/02 , C07K2319/03 , C12N2502/11 , C12N2502/99 , C12N2510/00
Abstract: Polypeptides comprising: (i) an MHC class I α polypeptide association domain, (ii) a transmembrane domain, and (iii) a signalling domain comprising an ITAM-containing sequence are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using such polypeptides.
